USE OF GLEASON SCORE, PROSTATE SPECIFIC ANTIGEN, SEMINAL VESICLE AND MARGIN STATUS TO PREDICT BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY

Abstract

Progression-free survival determined by the model score group identified a wide range of risk levels for patients with specimen confined prostate cancer. This simple predictive model allows identification of patients at high risk for cancer progression with specimen confined disease who may be targeted for closer surveillance and adjuvant therapy, while those at lower risk may be simply observed.